期刊文献+

盐酸氢吗啡酮在不同条件下的稳定性研究 被引量:3

Stability Study of Hydromorphone Hydrochloride Under Different Conditions
原文传递
导出
摘要 目的考察盐酸氢吗啡酮注射液在不同条件下的稳定性,为临床合理用药提供依据。方法模拟临床鞘内给药剂量,将盐酸氢吗啡酮溶于生理盐水中,分别储存于自控镇痛泵(PVC)、玻璃瓶(非PVC)、普通注射器(PVC)中。在25,37℃下,采用HPLC测定盐酸氢吗啡酮第0,1,2,3,5,7,9,11,13,15天的药物浓度,观察外观变化并测定其pH值。结果在不同温度、不同时间点,盐酸氢吗啡酮注射液在自控镇痛泵、玻璃瓶、普通注射器中浓度、外观及pH值均无明显变化,15 d内保持稳定。结论在临床实践中,将盐酸氢吗啡酮注射液分别加入含生理盐水40 m L的自控镇痛泵、玻璃瓶、普通注射器中,使其浓度为0.05 mg·m L^(-1),在输液器内保存10 d以上是可行的。 OBJECTIVE To investigate the stability of hydromorphone hydrochloride solution in different conditions in order to provide the references information for rational drug in clinical practice. METHODS In a simulated clinical situation, hydromorphone hydrochloride was undergone appropriate dilution with 0.9% sodium chloride injection and was stockpiled in infusion bags(PVC), infusion bags(non-PVC) or drug infusion pumps(PVC). Then HPLC was employed to determine hydromorphone concentrations at 0, 1, 2, 3, 5, 7, 9, 11, 13, 15, 17 d under 25 ℃ or 37 ℃. The appearance was observed and the p H was measured. RESULTS No notable changes in p H or appearance were observed at different temperatures, different time and implantable infusion system for 15 d. CONCLUSION It is appropriate that 0.05 mg·m L^(-1) hydromorphone hydrochloride is in 40 m L 0.9% sodium chloride injection in different implantable infusion system to keep stable for at least 10 d from the perspective of drug stability.
出处 《中国现代应用药学》 CAS CSCD 2017年第8期1150-1153,共4页 Chinese Journal of Modern Applied Pharmacy
基金 河北省卫生厅医学科学研究项目(20150368)
关键词 盐酸氢吗啡酮 自控镇痛泵 稳定性 PVC输液袋 非PVC输液袋 hydromorphone hydrochloride patient controlled analgesia stability PVC infusion bags non-PVC infusion bags
  • 相关文献

参考文献2

二级参考文献27

  • 1Kumar P, Sunkaraneni S, Sirohi S, et al. Hydromorphone efficacyand treatment protocol impact on tolerance and mu-opioid receptorregulation. Eur J Pharmacol, 2008, 597(1-3):39-45.
  • 2Felden L, Walter C, Harder S, et al. Comparative clinical effectsof hydromorphone and morphine: a meta-analysis. Br J Anaesth, 2011, 107(3):319-328.
  • 3Lussier D, Richarz U, Finco G. Use of hydromorphone, withparticular reference to the OROS formulation, in the elderly. Drugs aging,2010, 27(4):327-335.
  • 4Davison SN, Mayo PR. Pain management in chronic kidneydisease: the pharmacokinetics and pharmacodynamics of hydromorphoneand hydromorphone-3-glucuronide in hemodialysis patients. J OpioidManag, 2008, 4(6):335-336, 339-344.
  • 5Rauch E. Intrathecal hydromorphone for postoperative analgesiaafter cesarean delivery: a retrospective study. AANA J, 2012, 80(4Suppl):S25-32.
  • 6Johansen MJ, Satterfield WC, Baze WB, et al. Continuousintrathecal infusion of hydromorphone: safety in sheep model and clinicalimplications. Pain Med, 2004, 5(1):14-25.
  • 7Rauch E. Intrathecal hydromorphone for cesarean delivery: insearch of improved postoperative pain management: a case report. AANA J.2011, 79(5):427-432.
  • 8Lee YS, Park YC, Kim JH, et al. Intrathecal hydromorphoneadded to hyperbaric bupivacaine for postoperative pain relief after kneearthroscopic surgery: a prospective, randomised, controlled trial. Eur JAnaesthesiol, 2012, 29(1):17-21.
  • 9Chang AK, Bijur PE, Lupow JB, et al. Randomized clinical trial ofthe 2 mg hydromorphone bolus protocol versus the "1 + 1" hydromorphonetitration protocol in treatment of acute, severe pain in the first hour ofemergency department presentation. Ann Emerg Med, 2013, 62(4):304-310.
  • 10Oldenmenger WH, Lieverse PJ, Janssen PJ, etal. Efficacy ofopioid rotation to continuous parenteral hydromorphone in advanced cancerpatients failing on other opioids. Support Care Cancer, 2012, 20(8):1639-1647.

共引文献70

同被引文献28

引证文献3

二级引证文献7

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部